Matrix metalloproteinase 9 and transglutaminase 2 expression at the ocular surface in patients with different forms of dry eye disease.
暂无分享,去创建一个
Pasquale Aragona | A. Roszkowska | P. Aragona | M. Aguennouz | M'Hammed Aguennouz | Laura Rania | Elisa Postorino | Margherita Serena Sommario | Anna Maria Roszkowska | Maria Grazia De Pasquale | Antonina Pisani | Domenico Puzzolo | E. Postorino | D. Puzzolo | A. Pisani | L. Rania | Margherita S Sommario | M. G. De Pasquale | M. D. De Pasquale
[1] I. Gipson,et al. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. , 2000, Archives of ophthalmology.
[2] Lee Stern,et al. Dysfunctional Tear Syndrome: A Delphi Approach to Treatment Recommendations , 2006, Cornea.
[3] K. Tsubota,et al. IL-6 induction in desiccated corneal epithelium in vitro and in vivo , 2011, Molecular vision.
[4] D. Dartt,et al. Modulation of Conjunctival Goblet Cell Function by Inflammatory Cytokines , 2013, Mediators of inflammation.
[5] De-Quan Li,et al. Production and activity of matrix metalloproteinase-9 on the ocular surface increase in dysfunctional tear syndrome. , 2009, Investigative ophthalmology & visual science.
[6] R. Jonsson,et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group , 2002, Annals of the rheumatic diseases.
[7] P. Aragona,et al. Sodium hyaluronate eye drops of different osmolarity for the treatment of dry eye in Sjögren's syndrome patients , 2002, The British journal of ophthalmology.
[8] A. Roszkowska,et al. Safety and Efficacy of 0.1% Clobetasone Butyrate Eyedrops in the Treatment of Dry Eye in Sjögren Syndrome , 2013, European journal of ophthalmology.
[9] S. Yeo,et al. Hyperosmolarity‐mediated mitochondrial dysfunction requires Transglutaminase‐2 in human Corneal epithelial cells , 2010, Journal of cellular physiology.
[10] P. Aragona,et al. Towards a dynamic customised therapy for ocular surface dysfunctions , 2013, British Journal of Ophthalmology.
[11] De-Quan Li,et al. IL-17 disrupts corneal barrier following desiccating stress , 2009, Mucosal Immunology.
[12] N. Bodor,et al. Metabolism, Distribution, and Transdermal Permeation of a Soft Corticosteroid, Loteprednol Etabonate , 1992, Pharmaceutical Research.
[13] S. Yeh,et al. Apoptosis of ocular surface cells in experimentally induced dry eye. , 2003, Investigative ophthalmology & visual science.
[14] Murat Dogru,et al. The international workshop on meibomian gland dysfunction: report of the clinical trials subcommittee. , 2011, Investigative ophthalmology & visual science.
[15] L. Benjamin,et al. Meibomian gland disease. Classification and grading of lid changes , 1991, Eye.
[16] J. McCulley,et al. Meibomian Gland Triglyceride Fatty Acid Differences in Chronic Blepharitis Patients , 1996, Cornea.
[17] W. Mathers. Meibomian gland disease , 2004 .
[18] G. Li Volti,et al. Effect of growth factors and steroids on transglutaminase activity and expression in primary astroglial cell cultures , 2008, Journal of neuroscience research.
[19] J. Shoji,et al. Regulation of soluble interleukin-6 (IL-6) receptor release from corneal epithelial cells and its role in the ocular surface , 2011, Japanese Journal of Ophthalmology.
[20] A. Bron,et al. Predicted phenotypes of dry eye: proposed consequences of its natural history. , 2009, The ocular surface.
[21] D. Zoukhri. Effect of inflammation on lacrimal gland function. , 2006, Experimental eye research.
[22] A. Tomlinson,et al. Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting. , 2013, The ocular surface.
[23] L. Fésüs,et al. Transglutaminase 2 in the balance of cell death and survival , 2005, FEBS letters.
[24] Marisa Meloni,et al. Molecular mechanism of ocular surface damage: Application to an in vitro dry eye model on human corneal epithelium , 2011, Molecular vision.
[25] H. Jun,et al. Transglutaminase type 2 in human abdominal aortic aneurysm is a potential factor in the stabilization of extracellular matrix. , 2013, Journal of vascular surgery.
[26] Jun Shimazaki,et al. The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee. , 2011, Investigative ophthalmology & visual science.
[27] M. Fini,et al. Matrix metalloproteinase-9 knockout confers resistance to corneal epithelial barrier disruption in experimental dry eye. , 2005, The American journal of pathology.
[28] S. Pflugfelder,et al. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome. , 1999, Ophthalmology.
[29] De-Quan Li,et al. Apical corneal barrier disruption in experimental murine dry eye is abrogated by methylprednisolone and doxycycline. , 2006, Investigative ophthalmology & visual science.
[30] A. Roszkowska,et al. Effects of amino acids enriched tears substitutes on the cornea of patients with dysfunctional tear syndrome , 2013, Acta ophthalmologica.
[31] S. Keshavjee,et al. MMP9 modulates tight junction integrity and cell viability in human airway epithelia. , 2009, American journal of physiology. Lung cellular and molecular physiology.
[32] P. Aragona,et al. Meibomian gland dysfunction and ocular discomfort in video display terminal workers , 2008, Eye.
[33] K. Yoon,et al. Hyperosmolarity-induced cornification of human corneal epithelial cells is regulated by JNK MAPK. , 2008, Investigative ophthalmology & visual science.
[34] Heesang Song,et al. Tissue transglutaminase 2 promotes apoptosis of rat neonatal cardiomyocytes under oxidative stress , 2011, Journal of receptor and signal transduction research.
[35] R. Dana,et al. The international workshop on meibomian gland dysfunction: report of the clinical trials subcommittee. , 2011, Investigative ophthalmology & visual science.
[36] Gerd Geerling,et al. Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007). , 2007, The ocular surface.
[37] M. Lemp. Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. , 1995, The CLAO journal : official publication of the Contact Lens Association of Ophthalmologists, Inc.
[38] De-Quan Li,et al. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. , 2006, Experimental eye research.
[39] Wenshu Chen,et al. Epidermal Growth Factor Receptor-mediated Tissue Transglutaminase Overexpression Couples Acquired Tumor Necrosis Factor-related Apoptosis-inducing Ligand Resistance and Migration through c-FLIP and MMP-9 Proteins in Lung Cancer Cells* , 2011, The Journal of Biological Chemistry.
[40] De-Quan Li,et al. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. , 2004, Investigative ophthalmology & visual science.
[41] S. Kojima,et al. Free fatty acids induce transglutaminase 2‐dependent apoptosis in hepatocytes via ER stress‐stimulated PERK pathways , 2012, Journal of cellular physiology.
[42] B. Glasgow,et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on tear film lipids and lipid-protein interactions in health and disease. , 2011, Investigative ophthalmology & visual science.
[43] J. Chodosh,et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. , 2004, American journal of ophthalmology.
[44] M. Raghunath,et al. Transglutaminase activity in the eye: cross-linking in epithelia and connective tissue structures. , 1999, Investigative ophthalmology & visual science.
[45] R. Beuerman,et al. Transglutaminase participates in UVB-induced cell death pathways in human corneal epithelial cells. , 2006, Investigative ophthalmology & visual science.
[46] Yunhee Lee,et al. Matrix Metalloproteinase Gelatinase B (MMP-9) Coordinates and Effects Epithelial Regeneration* , 2002, The Journal of Biological Chemistry.
[47] M. Musumeci,et al. Acidic Mammalian Chitinase in Dry Eye Conditions , 2009, Cornea.
[48] P. Aragona,et al. Comparison of ocular surface disease index and tear osmolarity as markers of ocular surface dysfunction in video terminal display workers. , 2014, American journal of ophthalmology.
[49] L. Wheeler,et al. Mitochondrial permeability transition pore in inflammatory apoptosis of human conjunctival epithelial cells and T cells: effect of cyclosporin A. , 2013, Investigative ophthalmology & visual science.
[50] Maya Ram,et al. Matrix Metalloproteinase-9 and Autoimmune Diseases , 2006, Journal of Clinical Immunology.
[51] Christophe Baudouin,et al. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). , 2007, The ocular surface.
[52] J. Mehta,et al. Comparative analysis of two femtosecond LASIK platforms using iTRAQ quantitative proteomics. , 2014, Investigative ophthalmology & visual science.